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Abstract
Aims/Hypothesis: Several studies have provided compelling evidence implicating the Wnt signalling pathway in the
pathogenesis of diabetic nephropathy. Gene expression profiles associated with renal fibrosis have been attenuated
through Wnt pathway modulation in model systems implicating Wnt pathway members as potential therapeutic targets for
the treatment of diabetic nephropathy. We assessed tag and potentially functional single nucleotide polymorphisms (SNPs;
n=31) in four key Wnt pathway genes (CTNNB1, AXIN2, LRP5 and LRP6) for association with diabetic nephropathy using a
case-control design.
Methods: SNPs were genotyped using Sequenom or Taqman technologies in 1351 individuals with type 1 diabetes (651
cases with nephropathy and 700 controls without nephropathy). Cases and controls were white and recruited from the UK
and Ireland. Association analyses were performed using PLINK, to compare allele and haplotype frequencies in cases and
controls. Adjustment for multiple testing was performed by permutation testing.
Results: Following logistic regression analysis adjusted by collection centre, duration of T1D, and average HbA1c as
covariates, a single SNP in LRP6 (rs1337791) was significantly associated with DN (OR=0.74; CI: 0.57–0.97; P=0.028),
although this was not maintained following correction for multiple testing. Three additional SNPs (rs2075241 in LRP6;
rs3736228 and rs491347 both in LRP5) were marginally associated with diabetic nephropathy, but none of the associations
were replicated in an independent dataset. Haplotype and subgroup analysis (according to duration of diabetes, and end-
stage renal disease) also failed to reveal an association with diabetic nephropathy.
Conclusions/Interpretation: Our results suggest that analysed common variants in CTNNB1, AXIN2, LRP5 and LRP6 are not
strongly associated with diabetic nephropathy in type 1 diabetes among white individuals. Our findings, however, cannot
entirely exclude these genes or other members of the Wnt pathway, from involvement in the pathogenesis of diabetic
nephropathy as our study had limited power to detect variants with small effect size.
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Introduction
Renal interstitial fibrosis and glomerular sclerosis are hallmarks
of diabetic nephropathy (DN) and several studies have implicated
the canonical Wnt pathway in this fibrotic process [1–2]. The
Wnt/b-catenin signalling pathway modulates numerous develop-
mental processes and mutations in Wnt/b-catenin pathway
members have been implicated in multiple diseases [3]. In
humans, 19 different specific Wnt ligands have been reported to
induce Wnt/b-catenin signalling [3]. These ligands bind to
transmembrane Frizzled (FZD) receptors and their co-receptors,
low-density lipoprotein receptor related proteins 5 or 6 (LRP5/
LRP6), forming a binding complex that recruits intracellular
scaffolding protein Dishevelled (Figure 1). This leads to phosphor-
ylation and sequestration of the Axin complex, which is composed
of the proto-oncogene adenomatous polyposis coli, casein kinase 1 and
glycogen synthase kinase 3, as well as the Axin protein itself. In the
absence of Wnt, the Axin complex phosphorylates the cytoplasmic
transcriptional coactivator b-catenin. This leads to subsequent
recognition by b-transducin repeat-containing protein, which
when ubiquitinated, promotes proteosomal degradation of b-
catenin. When the Axin complex and Wnt ligands combine, b-
catenin phosphorylation and ubiquitination ceases. The resultant
stabilisation of intracellular b-catenin facilitates its translocation
from the cytoplasm to the nucleus, where it interacts with
transcription factors of the T-cell factor/lymphoid enhancer-
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genes [3].
TGFb1-induced epithelial-to-mesenchymal cell transition
(EMT) promotes renal fibrosis [4], a characteristic pathological
feature of DN. TGFb1, integrin-linked kinase and Wnt pathways
converge upon activation of b-catenin and EMT is initiated,
implicating b-catenin as a master controller of multiple pathways.
Furthermore, membrane bound E-cadherin/b-catenin complexes,
which form the cell-to-cell junctions typical of an epithelial cell
type, are lost during TGF-b1 and IGF-I induced EMT [5]. In
addition, inhibition of GSK3b has been shown to prevent
mesenchymal transition in human embryonic stem cells [6]. It is
estimated that there are more than 1800 Wnt pathway gene
targets [7] including transcription factor c-Myc, matrix metallo-
protease MMP-7, endothelin-1, and fibronectin (a marker of
fibrosis) [8]. Increased expression of Wnt-4 is associated with the
deposition of fibronectin [9].
Variation in expression profiles of many Wnt ligands, FZD
receptors and b-catenin have been reported in the unilateral
ureteral obstruction (UUO) mouse model of renal injury and
reduction in interstitial injury identified in response to dickkopf
homolog 1 (DKK-1), a Wnt signalling antagonist [1]. Indepen-
dently, DKK-1 was also shown to promote hyperglycaemia-
induced mesangial matrix accumulation and renal dysfunction in
rat mesangial cells [2]. Comparison of injury models is difficult;
nonetheless existing evidence implicates Wnt signalling in the
pathology of DN.
Our study was designed to assess association of common single
nucleotide polymorphisms (SNPs) in four key genes of the
canonical Wnt/b-catenin signalling pathway (AXIN2, CTNNB1,
LRP5 and LRP6) with DN using a case-control design involving
1467 individuals with type 1 diabetes. These genes were selected
on the basis of their functional significance as key components of
the Wnt signalling pathway and from differential expression
profiles derived from human kidney biopsy material from DN
cases compared to no nephropathy control samples. CTNNB1
encodes the b-catenin protein, the major effector of the pathway
responsible for transducing the Wnt activated signal from the
cytoplasm to the nucleus and subsequent transcriptional activation
of Wnt responsive genes. Both LRP5 and LRP6 are co-receptors
specific to the canonical Wnt pathway enabling detection of the
Wnt ligands. AXIN2 is a key component of the destruction
complex, which in the absence of a Wnt ligand, marks b-catenin
for ubiquitin-dependent proteolytic degradation, thus preventing
its translocation from the cytoplasm to the nucleus and subsequent
transcriptional activation.
Methods
Participants
Ethics approval was obtained from the appropriate Research
Ethics Committees, and written informed consent obtained prior
to participation. All recruited individuals were white, had type 1
diabetes mellitus (T1D) diagnosed before 32 years of age and were
born in the UK or Ireland. Patients (n=718) and controls
(n=749) were from the Warren 3/UK Genetics of Kidneys in
Diabetes (GoKinD) and all-Ireland collections [10]. The definition
of DN in cases was based on development of persistent proteinuria
(.0.5 g protein/24 h) at least 10 years after diagnosis of T1D,
hypertension (blood pressure.135/85 mmHg or treatment with
antihypertensive agents) and associated diabetic retinopathy.
Controls were individuals with T1D for at least 15 years with
normal urinary albumin excretion rates and no evidence of
microalbuminuria on repeated testing. In addition, control
subjects had not been prescribed antihypertensive drug treatment
avoiding possible misclassification of diabetic individuals as
‘control phenotypes’ when the use of antihypertensive treatment
may have reduced urinary albumin excretion into the normal
Figure 1. Schematic representation of the canonical Wnt signalling pathway. Gene names represented: Dishevelled (DSH), adenomatous
polyposis coli (APC), low-density lipoprotein receptor related proteins (LRP), casein kinase 1 (CK1a), glycogen synthase kinase 3 (GSK3- b), b-transducin
repeat-containing protein (b-TrCP), T-cell factor (TCF)/lymphoid enhancer factor (LEF), Wilms tumor-suppressor (WTX), Frizzled (FZD), dickkopf
homolog 1.
doi:10.1371/journal.pone.0023904.g001
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either case or control groups since it is not possible to confidently
assign a case or control definition upon such individuals with
microalbuminuria as their urinary albumin excretion may either
regress or progress over time [11].
SNP selection and genotyping
Tag SNPs for each gene investigated were selected from
Phase III, release 2 HapMap (http://www.hapmap.org) CEPH
data (Utah residents with ancestry in northern and western
Europe; CEU) using Haploview (http://www.broadinstitute.
org/haploview) to visualise linkage disequilibrium. Tag SNPs
were selected using multimarker tagging where r2.0.8 (LOD
threshold 3.0) for all downloaded SNPs with a minor allele
frequency (MAF) $5%, genotype call rate $95%, and no
deviation from Hardy–Weinberg equilibrium (HWE). Addition-
al potentially functional SNPs were identified using the Ensembl
genome browser (www.ensembl.org).
Genotyping was performed by MassARRAY iPLEX (Seque-
nom, San Diego, CA, USA) or Taqman 59 nuclease (Applied
Biosystems, Foster City, CA, USA) assays according to the
manufacturers’ instructions. Quality filters for exclusion of SNPs
included call rates below 95% and deviation from HWE
(P,0.001). DNA samples were excluded if missing genotypes
exceeded 10%. Other quality control measures included parent/
offspring trio samples, duplicates on plates, random sample
allocation to plates, independent scoring of problematic genotypes
by two individuals and re-sequencing of selected DNAs to validate
genotypes.
Statistical analysis
Clinical characteristics of cases and controls were compared
using the z-test for large independent samples and the x
2 test.
Association analyses were performed using PLINK (version 1.07;
http://pngu.mgh.harvard.edu/ ˜purcell/plink/). Initially a x
2 test
for trend (1 df) was used with stratification by collection centre.
Logistic regression analysis was performed on each SNP with
terms for potential confounders (collection centre, sex, duration
of T1D and HbA1c) included in the model. The level of
statistical significance was set at 5% and adjustment for multiple
testing performed by permutation test (n=100,000). In silico
replication of the most significant SNPs was sought through data
extracted from the US Genetics of Kidneys in Diabetes (US
GoKinD) study [12] available on dbGAP (http://www.ncbi.nlm.
nih.gov/gap, dataset phs000018.v2) which was based on a
stratified analysis of 935 DN cases and 944 no nephropathy
controls. The US GoKinD genotyping was performed on the
Affymetrix 5.0 SNP array (Affymetrix, Santa Clara, CA, USA).
Although only one of the four most significant SNPs identified
from this study was genotyped directly on this platform,
surrogate markers in high LD based on 1000 Genomes pilot
data (http://www.1000genomes.org/), were used as a proxies for
the other three. Potential gene-gene interactions between the
most significant SNPs were assessed using likelihood ratio x
2 tests
in the logistic regression.
Results
The clinical characteristics of the DN cases (n=651) and
diabetic controls (n=700) genotyped in this study which met
quality control filters are listed in Table 1. The average genotyping
rate was 98.6%. There were more males, higher mean HbA1c and
blood pressure values (despite the use of antihypertensive
treatment) in the case group compared with the control group.
All comparisons were significant at P,0.001 with the exception of
age at diagnosis which did not differ significantly between groups.
Approximately one quarter of cases (25.4%) had end-stage renal
disease (ESRD).
We excluded 116 samples (67 patients and 49 controls) from the
analysis with $10% missing genotypes. A total of 31 SNPs were
genotyped, 28 using MassARRAY iPLEX technology, and 3 SNPs
by Taqman 59 nuclease assay in 651 cases and 700 controls
(Table 2). The average call rate for all SNPs analysed was 98.65%.
The genotype distribution for each SNP did not deviate
significantly from HWE in either cases or controls. No duplicate
or Mendelian inconsistencies were observed.
Table 1. Clinical characteristics of diabetic nephropathy (DN) cases and diabetic controls.
Characteristic
DN cases
(n=651)
Controls
(n=700)
Male; n (%) 374 (57.5%) 299 (42.7%)
Age at diagnosis of T1D (yr) 14.767.6 15.467.9
Duration of T1D (yr)
a 33.269.3 28.068.9
HbA1c (%)
b 9.161.9 8.661.5
Systolic blood pressure (mmHg)
b 145.0621.0 124.9614.4
Diastolic blood pressure (mmHg)
b 81.7611.5 75.467.8
Body mass index (kg/m
2) 26.464.8 26.264.2
Serum cholesterol (mmol/L) 5.3561.25 5.0960.92
Serum creatinine (mmol/L);
c median (interquartile range) 130 (103–183) 91 (77–105)
Glomerular filtration rate (ml/min/1.73m
2);
cmedian (interquartile range) 48 (34–66) 70 (60–87)
End-stage renal disease n (%) 165 (25.3%) NA
Unless otherwise stated values are mean 6 standard deviation.
aCalculated from the dates of diagnosis and recruitment.
bAverage of the three most recent values prior to recruitment.
cExcludes subjects receiving renal replacement therapy (dialysis or transplant).
P,0.05 for age at diagnosis; P,0.001 for all other comparisons except body mass index.
doi:10.1371/journal.pone.0023904.t001.
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Case Control Confidence
Gene SNP
aAlleles Counts MAF Counts MAF
bOR Interval
cP
LRP6 rs10466849 [T/C] 23/143/480 0.15 17/200/479 0.17 0.88 0.69–1.12 0.301
LRP5 rs11228202 [T/C] 15/146/489 0.14 9/159/531 0.13 1.10 0.84–1.44 0.486
CTNNB1 rs11564465 [T/C] 144/297/210 0.45 171/315/213 0.47 0.93 0.78–1.10 0.394
LRP5 rs11823032 [A/G] 53/276/288 0.31 72/297/316 0.32 0.91 0.74–1.10 0.324
AXIN2 rs11868547 [C/G] 140/336/175 0.47 158/331/209 0.46 1.00 0.84–1.19 0.981
AXIN2 rs12452196 [A/G] 12/160/479 0.14 15/165/519 0.14 1.11 0.86–1.43 0.425
LRP6 rs13377971 [A/G] 15/108/525 0.11 13/157/529 0.13 0.74 0.57–0.97 0.028
LRP6 rs2075241 [C/G] 30/192/429 0.19 17/173/510 0.15 1.24 0.98–1.56 0.075
AXIN2 rs2240308 [G/A] 167/304/178 0.49 161/349/187 0.48 1.06 0.89–1.26 0.53
LRP5 rs2242340 [T/C] 7/140/478 0.12 8/155/498 0.13 0.96 0.73–1.27 0.773
LRP6 rs2300230 [C/T] 4/78/564 0.07 5/85/609 0.07 1.20 0.84–1.71 0.318
LRP6 rs2302685 [C/T] 19/208/403 0.20 22/207/441 0.19 1.05 0.83–1.33 0.663
LRP6 rs2417085 [C/T] 153/282/166 0.49 142/327/201 0.46 1.03 0.86–1.24 0.742
LRP5 rs312014 [C/G] 79/312/260 0.36 92/289/318 0.34 1.10 0.91–1.32 0.335
LRP5 rs312016 [A/G] 49/273/329 0.28 59/246/394 0.26 1.11 0.91–1.35 0.297
LRP5 rs3736228 [T/C] 14/180/437 0.16 11/166/509 0.14 1.27 0.98–1.64 0.066
LRP6 rs3741792 [T/C] 4/72/573 0.06 4/82/612 0.06 1.22 0.85–1.76 0.28
LRP5 rs3781600 [C/G] 12/117/522 0.11 4/127/569 0.10 1.15 0.86–1.55 0.346
AXIN2 rs3923086 [T/G] 136/297/217 0.44 140/331/229 0.44 1.06 0.89–1.26 0.492
AXIN2 rs4074947 [T/C] 28/214/409 0.21 23/250/427 0.21 0.89 0.71–1.11 0.29
AXIN2 rs4128941 [A/G] 0/58/581 0.05 1/55/628 0.04 1.14 0.73–1.77 0.569
AXIN2 rs4541111 [T/G] 162/314/171 0.49 189/320/185 0.50 0.89 0.75–1.06 0.206
AXIN2 rs4791171 [A/G] 53/286/310 0.30 67/285/348 0.30 1.03 0.85–1.25 0.77
LRP5 rs491347 [C/T] 38/285/325 0.28 35/272/391 0.24 1.22 0.99–1.51 0.062
LRP5 rs4930573 [G/C] 35/238/378 0.24 34/249/417 0.23 1.05 0.85–1.30 0.669
LRP5 rs587397 [G/C] 2/109/540 0.09 12/106/582 0.09 0.96 0.71–1.31 0.804
AXIN2 rs7224837 [G/A] 6/126/491 0.11 12/145/515 0.13 1.01 0.76–1.34 0.96
LRP6 rs7305037 [C/T] 119/312/191 0.44 149/329/192 0.47 0.99 0.82–1.19 0.903
AXIN2 rs740026 [A/G] 128/307/212 0.44 122/356/215 0.43 1.00 0.83–1.20 0.996
LRP5 rs74744 [C/T] 110/313/228 0.41 125/349/226 0.43 0.90 0.75–1.08 0.258
AXIN2 rs757558 [T/G] 25/155/443 0.16 18/162/470 0.15 1.20 0.94–1.53 0.142
aMinor alleles are presented first followed by major allele.
bOdds ratios and 95% confidence intervals are calculated on a per allele basis for the first-mentioned allele assuming an additive model.
cP values were calculated as tests for trend (1 df) across genotypes and are adjusted by centre, gender, duration of disease and HbA1c level. Associations were no longer
significant after adjustment for multiple testing performed by permutation test (n=100,000).
doi:10.1371/journal.pone.0023904.t002
Table 3. Association analysis from the independent US Genetics of Kidneys in Diabetes study for the 4 most significant SNPs
identified from this study.
Gene SNP Affymetrix 5.0 proxy SNP r
2 Alleles P-Value Odds Ratio (C.I.)
LRP6 rs2075241 rs16907810 0.95 [C/T] 0.96 0.99 (0.83–1.18)
LRP5 rs3736228 [T/C] 0.53 1.06 (0.87–1.29)
LRP5 rs491347 rs576118 1 [G/A] 0.61 1.04 (0.88–1.22)
LRP6 rs13377971 rs11054710 1 [A/G] 0.32 0.89 (0.71–1.12)
These data were extracted from publicly available data on dbGAP (http://www.ncbi.nlm.nih.gov/gap, dataset phs000018.v2) and are based on a stratified analysis of 935
cases and 944 controls [12]. The genotyping was performed on the Affymetrix 5.0 SNP array. Although only one of the most significant SNPs identified from this study
was genotyped directly on this platform, surrogate markers in high LD based on 1000 Genomes pilot data (http://www.1000genomes.org/), were used as proxies for the
remaining 3 SNPs.
doi:10.1371/journal.pone.0023904.t003
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one SNP (rs1337791 in LRP6) significantly associated and three
SNPs (rs2075241 in LRP6; rs3736228 and rs491347 both in LRP5)
marginally associated with DN. Following logistic regression
analysis adjusted by collection centre, duration of T1D, and
average HbA1c as covariates, a single SNP (rs1337791) was
significantly associated with DN (OR=0.74; CI: 0.57–0.97;
P=0.028; Table 2), however this was not maintained following
correction for multiple testing. Haplotype analysis did not improve
association over single marker analysis. Subgroup analyses on the
basis of ESRD status showed no stronger association with ESRD
compared to those calculated for DN. Follow-up evaluation of the
top 4 significant associations in this study were not supported
within the independent US GoKinD dataset (Table 3).
Having no prior hypotheses about interactions between SNPs
within the genes analysed in this study, we assumed a more
stringent level of significance (P,0.01) in assessing interactions. No
evidence supporting interaction was observed (Table 4 and Table
S1).
Discussion
Expansion of the mesangium is a well recognised histological
feature of DN that occurs early in renal dysfunction. Lin and
colleagues [2] showed that reduced expression of the endogenous
inhibitor, DKK-1, which binds Wnt co-receptors LRP5/6,
decreased diabetes-induced glomerular injury preventing hyper-
glycaemia-induced mesangial cell dysfunction. This homeostatic
interaction between b-catenin and DKK-1 in mesangial cell
function may result in variable b-catenin activity under different
physiological and pathological conditions in renal tissue. In
addition, they reported modulation of DKK-1, TGF-b1, and
fibronectin expression through RNA interference suggesting a
novel potential therapeutic target for DN [2].
Our study focused on the canonical Wnt pathway although
other Wnt pathways exist, including Wnt/Ca
2+ pathway and the
planar cell polarity pathway which could also conceivably
contribute to the pathogenesis of DN. The genes assessed in
this study were chosen on the basis of gene expression profiles
derived from human kidney biopsy samples of DN (unpublished
data). Although the four genes investigated did not demonstrate
significant association following correction for multiple testing,
independent replication or provide evidence of significant
interaction, additional untested variants within the canonical
and non-canonical Wnt pathways remain untested. To our
knowledge, this is the first association study in DN to assess
common variation within key genes regulating the Wnt pathway.
Interestingly, novel splice variants were proposed to modulate
Wnt pathway gene expression through mRNA stability and
enhanced translational efficiency [13]. Since our study focused
only on common variants, untyped, highly penetrant rare
variants within these genes could also be associated with DN.
Based on sample sizes used here and considering Bonferroni
correction for 31 comparisons, our study provides 90% power to
identify an allele with an odds ratio of 1.69, 1.50, 1.44 and 1.42
whose frequency in controls is 10%, 20%, 30% and 40%
respectively. However, this study has insufficient power to detect
effect sizes of smaller magnitude with odds ratios of 1.2/1.3
which are more often seen in common complex diseases
(Table 5). Other factors such as copy number variation or
epigenetic mechanisms (e.g. DNA methylation, microRNAs)
may alter gene function affecting these pathways, contributing to
disease risk.
In conclusion, we found no strong association between common
variants in the CTNNB1, AXIN2, LRP5, and LRP6 genes and DN.
Further work to investigate other members of the Wnt/b-catenin
or non-canonical pathways may identify potential risk factors for
genetic susceptibility to DN.
Supporting Information
Table S1 Assessment of gene-gene pair-wise interac-
tions. P values for gene-gene interactions were calculated from
likelihood ratio x
2 tests in the logistic regression with adjustment
for centre, gender, duration of type 1 diabetes and HbA1c. Three
attained significance at the P,0.01 level and are underlined. Were
the comparisons to have been independent then four would have
been expected to attained significance at the P,0.01 level by
chance purely as a consequence of multiple testing.
(DOC)
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Table 4. Assessment of gene-gene pair-wise interactions.
SNP rs13377971 rs2075241 rs3736228
rs13377971
rs2075241 0.026
rs3736228 0.790 0.459
rs491347 0.064 0.633 0.205
P values for gene-gene interactions were obtained between the four most
significant SNPs using likelihood ratio x
2 tests in the logistic regression. None
attained significance at the P,0.01 level.
doi:10.1371/journal.pone.0023904.t004
Table 5. Study power to detect various odds ratios for
selected minor allele frequencies.
Minor Allele Frequency (MAF)
0.10 0.20 0.30 0.40
Odds ratio 1.2 29% 48% 59% 64%
1.3 55% 80% 88% 92%
1.4 78% 95% 98% 99%
1.5 92% 99% 100% 100%
Power calculations are based on 650 cases and 700 controls with odds ratio
ranging from 1.2–1.5 for SNPs with a MAF between 0.10 and 0.40 with no
adjustment for multiple testing. Corresponding figures after adjustment are
given in the Discussion.
doi:10.1371/journal.pone.0023904.t005
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